| Jun 15 |
Swelling losses haven't held back gains for Agios Pharmaceuticals (NASDAQ:AGIO) shareholders since they're up 71% over 1 year
|
| Jun 15 |
Agios Presents Positive Results from Phase 3 ENERGIZE Study of Mitapivat in Non-Transfusion-Dependent Thalassemia in Plenary Session at the European Hematology Association 2024 Hybrid Congress
|
| Jun 13 |
Prestige Consumer Healthcare (PBH) Down 0.4% Since Last Earnings Report: Can It Rebound?
|
| Jun 12 |
Agios Pharmaceuticals: Potential Acquisition Target, Upcoming FDA Approvals, Promising Pipeline
|
| Jun 9 |
Novavax And Agios Pharmaceuticals Were Among The 10 Biggest Mid-Cap Gainers Last Week (June 1-June 7): Are These In Your Portfolio?
|
| Jun 7 |
Insider Sale: CEO Brian Goff Sells Shares of Agios Pharmaceuticals Inc (AGIO)
|
| Jun 6 |
Updated Time: Agios to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024 at 8:40 am ET
|
| Jun 4 |
Agios (AGIO) Up 21% on Upbeat Data From 2nd Thalassemia Study
|
| Jun 3 |
Agios Announces Phase 3 ENERGIZE-T Study of Mitapivat Met Primary Endpoint and All Key Secondary Endpoints in Adults with Transfusion-Dependent Alpha- or Beta-Thalassemia
|
| May 30 |
Agios to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024
|
